Gene editing systems and uses thereof
AssigneeCorrectsequence Therapeutics (Shanghai) Co., Ltd
InventorsLijie WANG, Yichuan WANG, Peixue LI, Lang ZHANG, Xiaodun MOU
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to a LigoRNA system, and LigoRNA-based gene editing systems and uses thereof. Specifically, this disclosure provides novel base editing systems to achieve genomic editing at the base level, which enables broad applications in life science research and clinical therapy and/or biotechnology development. Also disclosed are polynucleotides, vectors, cells, and kits comprising components of the gene editing systems.
Claims40
-24. (canceled)
A gene editing system comprising a helper crRNA (hcrRNA) and a main crRNA (mcrRNA), or at least one DNA polynucleotide encoding the hcrRNA and/or the mcrRNA, wherein the hcrRNA comprises a first spacer sequence and a first linker sequence, wherein the first linker sequence comprises a first protein-binding motif, and the mcrRNA comprises a second spacer sequence and a second linker sequence, wherein the second linker sequence optionally comprises a second protein binding motif.
-28. (canceled)
-58. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-72. (canceled)
(canceled)
-82. (canceled)
Dependencies are inferred from the claim text.